NOVAVAX INC - 8-K Filing
Novavax earns $125 million milestone payment following Sanofi's dosing of fifth patient in Phase 3 influenza-COVID-19 combination vaccine trial. (Items: 7.01 Regulation FD Information, 8.01 hereof, 9.01 Financial Statements and Exhibits)
Tickers: $NVAX
Read the full article at SEC EDGAR
Part of the story Equillium, Inc. - 8-K Filing (3 articles)